Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (NASDAQ: TLSA) announced the online publication of two abstracts on its drug Milciclib at the ASCO20 meeting. The Phase 2a study showed Milciclib was well-tolerated in sorafenib-resistant hepatocellular carcinoma (HCC) patients, meeting primary endpoints with no drug-related deaths. Results indicated a 61% clinical benefit rate and a median progression-free survival of 5.9 months. Additionally, preliminary data from an ongoing trial combining Milciclib with Regorafenib showed a 20% reduction in AFP levels in liver transplant patients with recurrent HCC.
Tiziana Life Sciences plc (Nasdaq: TLSA) announces a new study on its StemPrintER genomic tool, showing its superiority over Oncotype DX in predicting breast cancer recurrence. Presented by scientists at the European Institute of Oncology at the upcoming ASCO Virtual Conference, the study highlights StemPrintER’s advanced prognostic capabilities in ER+/HER2- breast cancer patients. An additional model, SPARE, further refines distant metastasis predictions. This advancement reinforces Tiziana’s position in precision medicine and opens new business avenues beyond existing therapeutic pipelines.
Summary not available.